{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(2)"],"submitter":["Gregory MH"],"pubmed_abstract":["<h4>Background</h4>Invasive fungal infections are a devastating complication of inflammatory bowel disease (IBD) treatment. We aimed to determine the incidence of fungal infections in IBD patients and examine the risk with tumor necrosis factor-alpha inhibitors (anti-TNF) compared with corticosteroids.<h4>Methods</h4>In a retrospective cohort study using the IBM MarketScan Commercial Database we identified US patients with IBD and at least 6 months enrollment from 2006 to 2018. The primary outcome was a composite of invasive fungal infections, identified by ICD-9/10-CM codes plus antifungal treatment. Tuberculosis (TB) infections were a secondary outcome, with infections presented as cases/100 000 person-years (PY). A proportional hazards model was used to determine the association of IBD "],"journal":["Crohn's & colitis 360"],"pagination":["otad010"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9999356"],"repository":["biostudies-literature"],"pubmed_title":["Corticosteroids Increase the Risk of Invasive Fungal Infections More Than Tumor Necrosis Factor-Alpha Inhibitors in Patients With Inflammatory Bowel Disease."],"pmcid":["PMC9999356"],"pubmed_authors":["Deepak P","Stwalley D","Mejia-Chew C","Spec A","Gremida A","Nickel KB","Olsen MA","Gregory MH","Ciorba MA","Rood RP"],"additional_accession":[]},"is_claimable":false,"name":"Corticosteroids Increase the Risk of Invasive Fungal Infections More Than Tumor Necrosis Factor-Alpha Inhibitors in Patients With Inflammatory Bowel Disease.","description":"<h4>Background</h4>Invasive fungal infections are a devastating complication of inflammatory bowel disease (IBD) treatment. We aimed to determine the incidence of fungal infections in IBD patients and examine the risk with tumor necrosis factor-alpha inhibitors (anti-TNF) compared with corticosteroids.<h4>Methods</h4>In a retrospective cohort study using the IBM MarketScan Commercial Database we identified US patients with IBD and at least 6 months enrollment from 2006 to 2018. The primary outcome was a composite of invasive fungal infections, identified by ICD-9/10-CM codes plus antifungal treatment. Tuberculosis (TB) infections were a secondary outcome, with infections presented as cases/100 000 person-years (PY). A proportional hazards model was used to determine the association of IBD ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2025-04-04T18:49:08.788Z","creation":"2025-04-04T18:49:08.788Z"},"accession":"S-EPMC9999356","cross_references":{"pubmed":["36911593"],"doi":["10.1093/crocol/otad010"]}}